期刊文献+

阿托伐他汀长期治疗纯合子家族性高胆固醇血症1例 被引量:10

The efficacy and safety of long-term atrovastatin therapy in one case of homozygote familial hypercholesterolemia
下载PDF
导出
摘要 目的 :观察阿托伐他汀对纯合子高胆固醇血症的长期调脂疗效及安全性。方法 :1例 16岁女性患者连续服用不同剂量阿托伐他汀 2年 ( 2 0~ 80mg/d) ,同时定期复查血脂及安全指标。 结果 :TC降低了 2 7.4% ,LDL C降低了 2 8.9% ,未见不良反应。结论 :阿托伐他汀长期治疗纯合子家族性高胆固醇血症是有效。 Objectives:To assess the longterm efficacy and safety of atrovastatin in one patient with homozygote familial hypercholesterolemia.Methods:The patient was a 16 years old girl and she was continuously treated with atrovastatin in different dosage(20~80mg/d)for 2 years.Blood cholesterol and safety parameters were measured periodically.Results:The total cholesterol and low density lipidcholesterol were decreased by 27.4% and 28.9% respectively and no ADRs were observed.Conclusions:Atrovastatin is an effective,safe,and tolerable agent for long term treatment of patient with homozygote familial hypercholesterolemia.
机构地区 中国医学科学院
出处 《中国新药杂志》 CAS CSCD 2000年第6期403-404,共2页 Chinese Journal of New Drugs
关键词 阿托伐他汀 纯合子 家族性高胆固醇血症 治疗 atorvastatin homozygote familial hypercholesterolemia
  • 相关文献

参考文献3

  • 1 陆宗良.脂质代谢异常与冠心病[A].见:陈在嘉、徐义枢、孔华宇主编.临床冠心病学[M].北京:人民军医出版社,1994.61~87
  • 2 Jone PH,Kafonek S,Laurora I,et al. Comparative dose efficacy of atorvastatinversus simvastatin, pravastatin, lovastatin, and fluvastatin in patients withhypercholesterolenia (The CURVES Study)[J].Am J Cardiol,1998,81(5)∶582~587
  • 3李健斋,傅得兴.高效他汀类降血脂新药阿托他汀[J].中国新药杂志,1999,8(5):294-298. 被引量:30

二级参考文献1

共引文献29

同被引文献63

  • 1邢燕,陈红,胡大一.停用他汀类药物对血管内皮一氧化氮合成的影响[J].中华内科杂志,2005,40(1):22-24. 被引量:7
  • 2Lee JD, Morrissey JR, Mikhailidis DP,et al. CARDS on the table:shouid everybody with type 2 diabetes take a statin[J]? Curr Med Res Opin, 2005,3 : 357-362.
  • 3Guclu F, Ozmen B, Hekimsoy Z,et al. Effects of a statin group drug, pravastatin;on the insulin resistance in patients with metabolic syndrong[J]. Bioned Pharmacother, 2004,10: 614-618.
  • 4Solomon DH, Finkelstein JS, Wang PS, et al. Statin lipidlowering drugs and bone mineral density[J]. Pharmaeoepidemiol Drug Saf, 2005,14:219-226.
  • 5Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bonemineral density, and fracture risk: Geelong Osteoporosis Study [J]. Arch Intern Med,2002,162:537-540.
  • 6Lupattelli G, Scarponi AM. Vatudo C, et al. Simvastatin increases bone mineral density in hypercholsterolemic postmenopausal women[J]. Metabolism, 2004,53 : 744-748.
  • 7Hatzigeorgiou C, Jackson JL Hydroxymethylalutary a reductase inhibitour and osteoporosis: a metaanalysis(J). Osteoporos Int, 2005,16(8) : 990-998.
  • 8Edwards CJ. Stains and bone morphogendktjd new pathways in boneformtion[J]. Annacad Med Singapore, 2002,31 : 245-247.
  • 9Bamer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture:results of 4 prospectiev studies and cumulative meta-analysis of observtional studies and controlled trials[J]. Arch Intern Med,2004,164: 146-152.
  • 10Bellosta S. Ferri N, Bernini F, et al. Non-lipid related effects of statins[J]. Ann Med,2000,32:164-176.

引证文献10

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部